Literature DB >> 34059526

Trajectories in HbA1c and other risk factors among adults with type 1 diabetes by age at onset.

Jon Edqvist1,2, Araz Rawshani1,2, Aidin Rawshani1,2, Martin Adiels1,3, Stefan Franzén4, Lena Bjorck1,2, Ann-Marie Svensson4, Marcus Lind1,5, Naveed Sattar6, Annika Rosengren7,2.   

Abstract

INTRODUCTION: In type 1 diabetes, potential loss of life-years is greatest in those who are youngest at the time of onset. Using data from a nationwide cohort of patients with type 1 diabetes, we aimed to study risk factor trajectories by age at diagnosis. RESEARCH DESIGN AND METHODS: We stratified 30 005 patients with type 1 diabetes aged 18-75 years into categories based on age at onset: 0-10, 11-15, 16-20, 21-25, and 26-30 years. HbA1c, albuminuria, estimated glomerular filtration rate (eGFR), body mass index (BMI), low-denisty lipoprotein (LDL)-cholesterol, systolic blood pressure (SBP), and diastolic blood pressure trends were analyzed using mixed models. Variable importance for baseline HbA1c was analyzed using conditional random forest and gradient boosting machine approaches.
RESULTS: Individuals aged ≥16 years at onset displayed a relatively low mean HbA1c level (~55-57 mmol/mol) that gradually increased. In contrast, individuals diagnosed at ≤15 years old entered adulthood with a mean HbA1c of approximately 70 mmol/mol. For all groups, HbA1c levels stabilized at a mean of approximately 65 mmol/mol by about 40 years old. In patients who were young at the time of onset, albuminuria appeared at an earlier age, suggesting a more rapid decrease in eGFR, while there were no distinct differences in BMI, SBP, and LDL-cholesterol trajectories between groups. Low education, higher age, and poor risk factor control were associated with higher HbA1c levels.
CONCLUSIONS: Young age at the diabetes onset plays a substantial role in subsequent glycemic control and the presence of albuminuria, where patients with early onset may accrue a substantial glycemic load during this period. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  albuminuria; cardiovascular system; diabetes mellitus; glycated hemoglobin A; type 1

Year:  2021        PMID: 34059526     DOI: 10.1136/bmjdrc-2021-002187

Source DB:  PubMed          Journal:  BMJ Open Diabetes Res Care        ISSN: 2052-4897


  2 in total

1.  An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes.

Authors:  Eduardo Cabrera-Rode; Ileana Cubas-Dueñas; Janet Rodríguez-Acosta; Yudith García-García; Yelena Torres-López; Claudia Prieto-Noa; Bárbara M Vázquez-Izada; Maité Ruíz-Reinoso; Ragmila Echevarría-Valdés; Aimee Álvarez-Álvarez; Emma Domínguez-Alonso; Ana Ibis Conesa-González; Teresa González-Calero; Erick Robles-Torres; Silvia Elena Turcios-Tristá; Elizabeth Senra-Estévez; Patricia Hernández-Casaña; Luis Sarmiento
Journal:  J Clin Med       Date:  2022-03-24       Impact factor: 4.241

2.  Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users.

Authors:  Arcelia Arrieta; Tadej Battelino; Andrea E Scaramuzza; Julien Da Silva; Javier Castañeda; Toni L Cordero; John Shin; Ohad Cohen
Journal:  Diabetes Obes Metab       Date:  2022-05-12       Impact factor: 6.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.